Results

Total Results: 1,187 records

Showing results for "weeks".

1. Executive Summary: Radiation Therapy for Metastatic Bone Disease: Effectiveness and Harms (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-265-radiation-bone-disease-summary.pdf
   August 01, 2023 - ) probably slightly increases the likelihood of overall pain response (pain improvement) within 4 weeks … favoring HDSF + No difference ++ >4 weeks to 12 weeks No difference ++ Small favoring … No difference ++ No evidence No difference ++ >4 weeks to 12 weeks No difference + No evidence … weeks and 26 weeks Small ++ No difference + 36 weeks Moderate + No evidence Pain, VAS Pain … weeks No difference + No evidence Quality of Life (Effect Size/SOE)a 8 weeks No difference +

2. Evidence Summary for Treatments for Acute Pain: A Systematic Review (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/cer-240-acute-pain-evidence-summary.pdf
   December 01, 2020 - Outcomes were analyzed at <1 day, 1 day to <1 week, 1 week to <2 weeks, 2 to <4 weeks, and ≥4 weeks. … , 2 to <4 weeks, or ≥4 weeks. … and at 4 weeks. … and at ≥4 weeks. … and ≥4 weeks.

3. Evidence Summary_Comparative Effectiveness Review No. 247_Interventional Treatments for Acute and Chronic Pain: Systematic Review (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-247-interventional-treatments-acute-chronic-pain-evidence-summary_0.pdf
   September 01, 2021 - Outcomes were analyzed at 1 to 2 weeks, 2 to 4 weeks, 1 to 6 months, 6 to 12 months, and 12 months and … (8 trials, N=918) (strength of evidence [SOE]: low at 1 to 2 weeks, moderate at other time points). … (SOE: insufficient for 1 to 2 weeks, moderate for 1 to 6 months and 12 months and longer, and high for … 2 to 4 weeks and 6 to 12 months) … ) and acute (e.g., 3 to 6 weeks) symptoms.

4. Cer-265-Radiation-Bone-Disease-App-F (xls file)
   effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-265-radiation-bone-disease-app-f.xlsx
   January 01, 2019 - ; Unclear, >8 weeks Yes at 8 weeks, Unclear >8 weeks Yes at 8 weeks, Unclear >8 weeks Yes at 8 weeks, … ; No, 52-78 weeks No Yes, 16 weeks; No, 52-78 weeks Yes Good Nilsson, 2013 (Subsequent publication … to Nilsson, 2007 above) Yes Yes Yes Yes Yes Yes Yes Yes, 16 weeks; No, 52-78 weeks No Yes, 16 weeks; … ; No, 8 weeks Unclear Yes, 4 weeks; No, 8 weeks Yes Poor Smeland, 2003 Unclear Unclear No Unclear Yes … Yes Yes Yes, 12 weeks; No, 26 weeks Yes Yes, 12 weeks; No, 26 weeks Yes Fair Sorensen, 1994 Unclear

5. Preterm-Birth-Terbutaline-Pump Surveillance (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/pdf/preterm-birth-terbutaline-pump_surveillance.pdf
   January 30, 2013 - Women between 32 weeks and 33 weeks of gestation (preterm)? d. … , < 32 weeks, <34 weeks, <37 weeks), mean prolongation of pregnancy (days), birth weight, ratio of birth … Women between 32 weeks and 33 weeks of gestation (preterm)? d. … , < 32 weeks, <34 weeks, <37 weeks), mean prolongation of pregnancy (days), birth weight, ratio of birth … weeks, 95% CI range: 0.43–0.48 weeks, 0.92–0.97 weeks).13,15-19 Most participants in the cohort

6. Preterm-Birth-Terbutaline-Pump Surveillance (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/related_files/preterm-birth-terbutaline-pump_surveillance.pdf
   January 30, 2013 - Women between 32 weeks and 33 weeks of gestation (preterm)? d. … , < 32 weeks, <34 weeks, <37 weeks), mean prolongation of pregnancy (days), birth weight, ratio of birth … Women between 32 weeks and 33 weeks of gestation (preterm)? d. … , < 32 weeks, <34 weeks, <37 weeks), mean prolongation of pregnancy (days), birth weight, ratio of birth … weeks, 95% CI range: 0.43–0.48 weeks, 0.92–0.97 weeks).13,15-19 Most participants in the cohort

7. A Randomized Trial of Epidural Glucocorticoid Injections for Spinal Stenosis: A Brief Summary of Findings for Clinicians (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/pdf/glucocorticoid-injections_clinician.pdf
   June 01, 2016 - (measured by the Roland-Morris Disability Questionnaire [RMDQ]) and leg pain from baseline to 6 weeks … The sec- ondary outcomes were improvement in function and leg pain at 3 weeks; the pro- portions of … ) and with substantial clinically meaningful improvement (≥50%) in disability and leg pain at 6 weeks … ; and scores at 3 and 6 weeks on six other measures of symptoms, func- tion, and satisfaction. … KEY FINDINGS »» At 6 weeks after injection, patients in both the glucocorticoids-plus-lidocaine group

8. App-E-Surv-Report-2-Nonopioid-Pharmacol-Chronic-Pain (xls file)
   effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-e-surv-report-2-nonopioid-pharmacol-chronic-pain.xlsx
   May 29, 2025 - of Pain Demographics Other Population Characteristics N Randomized N Analyzed Intervention Duration (Weeks … of Pain Demographics Other Population Characteristics N Randomized N Analyzed Intervention Duration (Weeks … of Pain Demographics Other Population Characteristics N Randomized N Analyzed Intervention Duration (Weeks … of Pain Demographics Other Population Characteristics N Randomized N Analyzed Intervention Duration (Weeks … of Pain Demographics Other Population Characteristics N Randomized N Analyzed Intervention Duration (Weeks

9. Untitled (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/related_files/hepatitis-c_surveillance.pdf
   December 01, 2015 - (12 weeks of pegylated interferon alfa-2a, ribavirin, and telaprevir followed by 12 weeks of pegylated … telaprevir for 24 weeks (12 weeks of triple therapy followed by 12 weeks of dual therapy) … (Group A) to triple therapy with PEG-IFNα/RBV for 4 weeks followed by PEG-IFNα/RBV for 44 weeks with … telaprevir for 24 weeks (12 weeks of triple therapy followed by 12 weeks of dual therapy) … (Group A) to triple therapy with PEG- IFNα/RBV for 4 weeks followed by PEG- IFNα/RBV for 44 weeks

10. Untitled (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/hepatitis-c_surveillance.pdf
    December 01, 2015 - (12 weeks of pegylated interferon alfa-2a, ribavirin, and telaprevir followed by 12 weeks of pegylated … telaprevir for 24 weeks (12 weeks of triple therapy followed by 12 weeks of dual therapy) … (Group A) to triple therapy with PEG-IFNα/RBV for 4 weeks followed by PEG-IFNα/RBV for 44 weeks with … telaprevir for 24 weeks (12 weeks of triple therapy followed by 12 weeks of dual therapy) … (Group A) to triple therapy with PEG- IFNα/RBV for 4 weeks followed by PEG- IFNα/RBV for 44 weeks

11. CER 215 Executive Summary: Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-215-depression-older-adults-executive-summary.pdf
    March 01, 2019 - Comparison/ Study design Acute Phase (< 12 weeks) (SOE) Continuation Phase (12 weeks to 48 weeks … ) (SOE) Continuation Phase (12 weeks to 48 weeks) (SOE) Maintenance Phase (>48 weeks) (SOE) SNRI … ) (SOE) Continuation Phase (12 weeks to 48 weeks) (SOE) Maintenance Phase (>48 weeks) (SOE) Mirtazapine … ) (SOE) Continuation Phase (12 weeks to 48 weeks) (SOE) Maintenance Phase (>48 weeks) (SOE) SSRI … ), but others evaluated only the continuation (12 weeks up to 48 weeks) or maintenance (beyond 48 weeks

12. App-E-Surv-Report-1-Nonopioid-Pharmacol-Chronic-Pain (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-e-surv-report-1-nonopioid-pharmacol-chronic-pain.xlsx
    May 29, 2025 - of Pain Demographics Other Population Characteristics N Randomized N Analyzed Intervention Duration (Weeks … of Pain Demographics Other Population Characteristics N Randomized N Analyzed Intervention Duration (Weeks … of Pain Demographics Other Population Characteristics N Randomized N Analyzed Intervention Duration (Weeks … of Pain Demographics Other Population Characteristics N Randomized N Analyzed Intervention Duration (Weeks

13. App-E-Surv-Report-3-Nonopioid-Pharmacol-Chronic-Pain (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-e-surv-report-3-nonopioid-pharmacol-chronic-pain.xlsx
    May 29, 2025 - of Pain Demographics Other Population Characteristics N Randomized N Analyzed Intervention Duration (Weeks … of Pain Demographics Other Population Characteristics N Randomized N Analyzed Intervention Duration (Weeks … of Pain Demographics Other Population Characteristics N Randomized N Analyzed Intervention Duration (Weeks … of Pain Demographics Other Population Characteristics N Randomized N Analyzed Intervention Duration (Weeks … of Pain Demographics Other Population Characteristics N Randomized N Analyzed Intervention Duration (Weeks

14. App-D-Surv-Report-3-Noninvasive-Nonpharma 0 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-d-surv-report-3-noninvasive-nonpharma_0.xlsx
    January 01, 2022 - per set for weeks 5 and 6, and 90% of the 1RM with 4 repetitions per set for weeks 7 and 8. … : 251 Analyzed at 52 weeks: 258 A. … After 12 weeks, brief check-in call every 6 weeks A vs. B vs. … : 251 Attrition at 26 weeks: 22% (69/320) Analyzed at 52 weeks: 258 Attrition at 52 weeks: 19% (62/320 … After 12 weeks, brief check-in call every 6 weeks A vs. B vs.

15. App-E-Surv-Rept-1-Acute-Pain (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-e-surv-rept-1-acute-pain.xlsx
    May 29, 2025 - and 1 year 1 week to >4 weeks A vs. … 2 weeks to <4 weeks ≥4 weeks A vs. … , p>0.05; 2.9 vs. 4.2 at 6 weeks, p>0.05 A vs. … , p=0.43; 77.9 (23.5) vs. 72.1(23.5) at 6 weeks, p=0.92 A vs. … , p=0.74; 56.3 (29.7) vs. 50.0 (25.0) at 6 weeks, p=0.17 A vs.

16. Hepatitis-C Executive (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/hepatitis-c_executive.pdf
    November 01, 2012 - (dual therapy with pegylated interferon alfa-2b plus ribavirin for 4 weeks followed by 44 weeks of … (12 weeks of pegylated interferon alfa-2a, ribavirin, and telaprevir followed by 12 weeks of pegylated … telaprevir for 24 weeks (12 weeks of triple therapy followed by 12 weeks of dual therapy). … (4 weeks of dual therapy lead-in with pegylated interferon plus ribavirin followed by 44 weeks of … therapy with pegylated interferon alfa-2a plus ribavirin for 48 weeks.

17. Treatment of Hepatitis C Virus Infection in Adults: Future Research Needs (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/hepatitis-c-treatment-future_research.pdf
    April 01, 2013 - of dual therapy with pegylated interferon (alfa-2a or alfa-2b) more effective than 12-16 weeks for … (12 weeks of pegylated interferon alfa-2a, ribavirin, and telaprevir followed by 12 weeks of pegylated … vs. dual therapy with pegylated interferon alfa-2a plus ribavirin for 48 weeks. … telaprevir for 24 weeks (12 weeks of triple therapy followed by 12 weeks of dual therapy). … (4 weeks of dual therapy lead-in with pegylated interferon plus ribavirin followed by 44 weeks of

18. App-D-Surv-Report-1-Noninvasive-Nonpharma 0 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-d-surv-report-1-noninvasive-nonpharma_0.xlsx
    January 01, 2021 - followed by 3-day intervals for 7 weeks B. … followed by twice a week for 3 weeks C. … per set for weeks 5 and 6, and 90% of the 1RM with 4 repetitions per set for weeks 7 and 8. … : 251 Analyzed at 52 weeks: 258 A. … After 12 weeks, brief check-in call every 6 weeks A vs. B vs.

19. App-D-Surv-Report-2-Noninvasive-Nonpharma (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-d-surv-report-2-noninvasive-nonpharma.xlsx
    January 01, 2021 - followed by 3-day intervals for 7 weeks B. … followed by twice a week for 3 weeks C. … per set for weeks 5 and 6, and 90% of the 1RM with 4 repetitions per set for weeks 7 and 8. … : 251 Analyzed at 52 weeks: 258 A. … After 12 weeks, brief check-in call every 6 weeks A vs. B vs.

20. Digestible Carbohydrate Intake and Maternal-Infant Outcomes: Appendix D Tables (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/carbohydrate-intake-appendix-d.xlsx
    January 01, 2019 - vs. moderately higher carbohydrate diet in women with obesity vs. women of normal weight 16 to 20 weeks … Nutrients calculated using a Nutrition Calculator (V2.7.3) Low-carbohydrate diet Between 24 and 28 weeks … ) and endpoint (36-37 weeks) FFQ (self-administered 360-item FFQ covering intakes during the previous … 4 weeks) Age, mean years (SD): 31.2 (4.4) BMI, median kg/m2 (10th-90th percentile): 32.6 (30.3-40.3) … gestation, and 28 weeks gestation 24-hour recalls at the 3 time periods Quintile 1 vs. quintile 2 vs